Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Could microorganisms in poop help treat the deadliest form of skin cancer?on August 16, 2019 at 7:34 am
Immunotherapy drugs stimulate a person's immune system to attack and destroy cancer. While they can significantly improve survival outcomes in those with melanoma, they are only effective in 40 to ...
- Buy Merck Stock Because Its Immunotherapy Drug Is a Game-Changer, Analyst Sayson August 16, 2019 at 6:17 am
Keytruda is a so-called anti-PD(L)1 inhibitor, one of a class of new immunotherapy drugs that uses the patient’s own immune system to fight cancer, and has had a major impact on cancer treatments.
- XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTICon August 15, 2019 at 10:30 pm
XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTIC XDX-01, a novel, point-of-care pre-treatment diagnostic, has completed early ...
- Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trialon August 15, 2019 at 10:30 am
IRVINE, Calif., Aug. 14, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing ...
- Merck's Cancer Immunotherapy Keytruda Continues to Aid Growthon August 15, 2019 at 5:30 am
The demand for checkpoint inhibitors, especially those targeting PD-1 and PD-L1, has risen significantly in the past couple of years. Cancer therapies that target either PD-1 or PD-L1 can stop ...
- Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapyon August 15, 2019 at 4:49 am
SLATE is an investigational immunotherapy directed at shared tumor-specific neoantigens (TSNA) which are derived from driver mutations, functionally important gene alterations recurrently observed in ...
- 2019 Edogawa NICHE Prize Awarded to Dr. Steven Rosenberg for His Pioneering Feat in Tackling Cancer with Immunotherapyon August 14, 2019 at 11:00 pm
The Edogawa NICHE Committee today announced that the 2019-Edogawa NICHE Prize (www.edogawanicheprize.org) has been awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective ...
- What is immunotherapy anyway? What you need to know about this exciting cancer treatmenton August 14, 2019 at 6:56 am
One of the most exciting advancements in cancer treatment in recent years is immunotherapy, which uses the body's own immune system to fight cancer. Many people became aware of immunotherapy when ...
- Better tools, better cancer immunotherapyon August 9, 2019 at 7:53 am
In the journal Science Immunology, researchers from DTU Health Technology and Jacobs University in Bremen have just published their cutting-edge research demonstrating advancement in detection of ...
- Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunitieson August 9, 2019 at 5:30 am
LAWRENCEVILLE, N.J, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics ...
via Bing News